Holen Sie sich die Stockscreener-App
12.45
5.06%
0.60
Vorhandelsmarkt:
12.40
-0.05
-0.40%
Crescent Biopharma Inc Aktie (CBIO) Neueste Nachrichten
Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Crescent Biopharma Announces Grants of Inducement Awards - The Manila Times
Can Crescent Biopharma Inc. (GKO0) stock sustain free cash flowWeekly Stock Recap & Trade Opportunity Analysis - Улправда
Is Crescent Biopharma Inc. (GKO0) stock dividend growth reliable2025 Growth vs Value & Safe Entry Trade Signal Reports - Улправда
Brokerages Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Target Price at $26.40 - Defense World
Huge insider buying in MGM and Salesforce - MSN
Frazier Life Sciences Management L.P. Takes Position in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
CBIO Insider Trading - Quiver Quantitative
GlycoMimetics executives to depart amid merger plans - MSN
BVF Inc. IL Makes New Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Braidwell LP Invests $4.22 Million in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma, Inc. (CBIO) Stock News & Articles - 24/7 Wall St.
Crescent Biopharma (NASDAQ:CBIO) Director Fairmount Funds Management Llc Purchases 1,360,000 Shares of Stock - Defense World
Crescent, Kelun in two-way deal, including PD-1/VEGF bispecific - BioWorld MedTech
Fairmount Funds Management Llc Purchases 1,360,000 Shares of Crescent Biopharma (NASDAQ:CBIO) Stock - MarketBeat
Shareholder Fairmount Funds Management LLC Buys 1,360,000 ($18.2M) Of Crescent Biopharma Inc [CBIO] - TradingView — Track All Markets
Kelun-Biotech and Crescent Biopharma forge strategic oncology partnership - Indian Pharma Post
Sichuan Kelun-Biotech partners with Crescent Biopharma for oncology advancements - MSN
Affinity Asset Advisors LLC Makes New $4.52 Million Investment in Crescent Biopharma, Inc. $CBIO - MarketBeat
Crescent Biopharma (NASDAQ:CBIO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
China's Kelun-Biotech licenses cancer treatment to Crescent Biopharma - Reuters
Crescent Biopharma (NASDAQ:CBIO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
Crescent Biopharma partners with Kelun-Biotech in oncology - BioWorld MedTech
Crescent and Kelun-Biotech swap cancer asset rights in double deal - Yahoo Finance
Check Out Crescent Biopharma Inc (CBIO)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Asia Deal Watch: Kelun And Crescent Partner And Cross-License Cancer Candidates - Citeline News & Insights
China’s Kelun-Biotech licenses cancer treatment to Crescent Biopharma - 1470 & 100.3 WMBD
Crescent Biopharma stock price target raised by Stifel to $32 on Kelun deal - Investing.com South Africa
Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Raises Target Price to $32 - 富途牛牛
Sichuan Kelun-Biotech biopharmaceutical partners with Crescent Biopharma - marketscreener.com
What's Happening With Crescent Biopharma Stock Today? - Benzinga
Crescent and Kelun-Biotech get creative with two-way licensing deal - The Pharma Letter
The Deal That Sent Crescent Biopharma Shares Surging Over 40% Pre-Market Today - Asianet Newsable
Why Is Crescent Biopharma Stock (CBIO) Up Today? - TipRanks
Kelun-Biotech and Crescent Biopharma announce strategic partnership - marketscreener.com
Kelun-Biotech And Crescent Biopharma Announce Strategic Partnership - TradingView — Track All Markets
Crescent Biopharma partners with Kelun-Biotech, raises $185 million By Investing.com - Investing.com Nigeria
Crescent Biopharma stock soars after Kelun-Biotech partnership By Investing.com - Investing.com South Africa
Crescent Biopharma IncKelun-Biotech Eligib - 富途牛牛
Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq
Crescent Biopharma partners with Kelun-Biotech, raises $185 million - Investing.com India
Kelun-Biotech and Crescent Biopharma form oncology partnership By Investing.com - Investing.com Australia
Kelun-Biotech and Crescent Biopharma… - digitalmore.co
Crescent Biopharma jumps after cancer drug partnership - TradingView — Track All Markets
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs - MarketScreener
Kelun-Biotech and Crescent Biopharma form oncology partnership - Investing.com
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics - PR Newswire
Is Crescent Biopharma Inc. (GKO0) stock a top hedge fund pickForecast Cut & Low Drawdown Momentum Trade Ideas - Newser
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors - GlobeNewswire
Kelun-Biotech and Crescent Biopharma Announce Strategic - GlobeNewswire
0.67%
1.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):